Vitamin D mitigates harm of modRNA spike proteins & fragments

A patient cohort study that recruited vaxxed injured adolescent modRNA recipients with suspected acute myocarditis and no serological evidence of prior SARS-COV-2 infection, between July 2021 and June 2022, and linked their electronic health records to vaccination records (n = 60), found that almost three-quarters of these patients were Vitamin D deficient or insufficient (73.3%) compared to convalescent samples. Calcifediol serum levels were found to be significantly inversely correlated with certain symptoms of myocarditis such as chest pain (88.3% of patients experiencing chest pain had lower calcifediol serum levels), shortness of breath, ICU admission and with cardiac muscle troponin levels (an indicator of stress and tissue damage). A separate assessment using peripheral blood mononuclear cells found that vitamin D insufficiency and deficiency was also inversely correlated with the frequency of natural killer cells with patients with calcifediol serum levels above 50 nanomoles/liter having the lowest frequencies of natural killer cells and lower levels of pro-inflammatory cytokines which suggests that calcifediol regulates inflammatory immune responses through a specific inhibitory cytokine profile on natural killer cells. In a subgroup of genotyped patients (n = 52), the study found that patients that carried a specific polymorphism for the vitamin D binding protein gene and vitamin D receptor gene had a corresponding higher risk of myocarditis. Tsang and colleagues, also found that patients with certain alleles in their genotype for natural killer cell activity were genetically predisposed to natural killer cell hyper-activation after exposure to the modRNA spike protein.

A retrospective cohort study conducted between August 2022 and February 2024 among patients who developed chronic fatigue syndrome and were admitted to the hospital after receiving the COVID vaxx (n = 28) found that vitamin D replacement therapy raised serum calcifediol levels from a mean 16 ng/mL to a mean 28 ng/mL over the observation period and 23/28 patients no longer met diagnostic criteria for chronic fatigue syndrome at the end. 20/28 reported improvements in sleep problems and 19/28 in autonomic symptoms while half reported improvements in pain.

A large systematic review of peer-reviewed epidemiological studies and RCTs evaluating the effect of calcitriol serum sufficiency (at least 50 ng/mL), insufficiency (>40 ng/mL) and deficiency (>20 ng/mL) on infection risk for SARS-COV-2 (n = 329) found a ‘strong association between vitamin D deficiency and increased susceptibility to complications and deaths from SARS-CoV-2’. Only 11 studies found no benefit due to a lack of sufficient controls, failure to measure baseline calcifediol serum levels, infrequent and unquantified doses, failure to use hard endpoints or using a single bolus dose. Some of these clinical trials did not even use vitamin D3 or calcifediol as the primary intervention. The other 318 studies included in this review found significant improvements in COVID-19 complications, hospitalization, ICU admissions, and mortality from calcifediol supplementation which met the Bradford Hill criteria for causality. As I pointed out in Vitamin D as a COVID-19 Prophylaxis, supplementation has been found to reduced SARS-COV-2 infection risk by as much as 80% among healthcare workers.